Literature DB >> 22865344

Airway hemangiomas in PHACE syndrome.

Megan L Durr1, Anna K Meyer, Kevin C Huoh, Ilona J Frieden, Kristina W Rosbe.   

Abstract

OBJECTIVES/HYPOTHESIS: To describe the clinical presentation and airway characteristics of infants with airway hemangiomas and concomitant PHACE syndrome and to determine the prevalence of airway hemangiomas in PHACE subjects at our institution. STUDY
DESIGN: Case series.
METHODS: Retrospective review including clinical presentation, airway findings, treatment measures, and outcomes.
RESULTS: A total of 23 subjects were diagnosed with definite PHACE at our institution between September 1, 2005 and September 1, 2011. Twelve (52%) of these subjects had documented airway hemangiomas, six of whom were diagnosed and treated at our institution. All six subjects underwent direct laryngoscopy and bronchoscopy by a pediatric otolaryngologist. Five (83%) subjects had subglottic hemangioma. Three subjects (50%) had additional hemangioma within the airway located on the epiglottis, vocal folds, posterior pharyngeal wall, and tracheal wall. Five subjects (83%) were treated with propranolol, five (83%) were treated with systemic steroids, and one subject received vincristine. One subject required laser ablation of subglottic hemangioma and tracheotomy. All subjects were airway symptom free at last follow-up (average, 35 months; range, 13-76 months).
CONCLUSIONS: Airway hemangiomas can be a life-threatening complication of PHACE syndrome. At our institution, 52% of all PHACE subjects were diagnosed with airway hemangiomas. Early detection of airway involvement is paramount. Given the high rates of airway hemangiomas, we recommend performing direct laryngoscopy and bronchoscopy in all PHACE patients with respiratory symptoms. We recommend having a low threshold for airway evaluation in asymptomatic PHACE patients, especially those who will not be otherwise started on propranolol.
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865344     DOI: 10.1002/lary.23475

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

1.  Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants.

Authors:  Denise Metry; Ilona J Frieden; Christopher Hess; Dawn Siegel; Mohit Maheshwari; Eulalia Baselga; Sarah Chamlin; Maria Garzon; Anthony J Mancini; Julie Powell; Beth A Drolet
Journal:  Pediatr Dermatol       Date:  2012-09-20       Impact factor: 1.588

Review 2.  The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies.

Authors:  Yin Lou; Wen-jia Peng; Yi Cao; Dong-sheng Cao; Juan Xie; Hong-hong Li
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

3.  Airway management and anesthesia in posterior fossa malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects and eye abnormalities syndrome: A case with laryngotracheal hemangiomas.

Authors:  Alper Kilicaslan; Atilla Erol; Ayse Ozlem Gundeslioglu; Ahmet Topal
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2014-10

4.  Noteworthy effects of a long-pulse Alexandrite laser for treatment of high-risk infantile hemangioma: A case report and literature review.

Authors:  Wen-Ting Su; Ji-Xin Xue; You-Hui Ke
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

5.  Mechanisms of propranolol action in infantile hemangioma.

Authors:  Jina Jy Kum; Zia A Khan
Journal:  Dermatoendocrinol       Date:  2015-01-26

6.  Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis.

Authors:  Jina J Y Kum; Zia A Khan
Journal:  Pediatr Res       Date:  2013-12-02       Impact factor: 3.756

7.  PHACE syndrome in antenatally diagnosed posterior fossa anomaly.

Authors:  Seema Pavaman Sindgikar; Uppoor Raghuraj; Kishan Alva; Thomas Mathen Maveli
Journal:  Indian Dermatol Online J       Date:  2014-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.